 |
answer text |
<p>The manufacture of cannabis-based medicines is allowed under the appropriate Medicines
and Healthcare products Regulatory Agency and Home Office licences. Cannabis-based
medicines must comply with all applicable requirements and high standards of manufacture
that apply to all other medicines to ensure patient safety.</p><p>In 2018, the Government
amended the law to allow specialist doctors to prescribe unlicensed cannabis-based
products for medicinal use, where clinically appropriate, with an accompanying impact
assessment published by the Home Office. The Government must consider advice from
the Advisory Council on the Misuse of Drugs (ACMD) before making any further amendments
to the law in this area. At the request of the Home Office, the ACMD have recently
reviewed this legislation and concluded that no amendments are currently required.</p><p>Cannabidiol
(CBD) in its pure form is not a controlled drug. However, many consumer CBD products
also contain varying amounts of controlled cannabinoids due to difficulties in isolating
pure CBD. The Home Office has sought the ACMD’s advice on a legal framework exempting
CBD products with a defined trace percentage of controlled cannabinoids from control
under the Misuse of Drugs Act 1971. The ACMD responded on December 17 2021 and the
Government is currently considering this advice.</p>
|
|
